These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 1186596)
41. History and philosophy of Bayer pharmaceutical research. Busse WD Arzneimittelforschung; 1989 Aug; 39(8A):935-7. PubMed ID: 2684180 [No Abstract] [Full Text] [Related]
42. Resurrection men dig through the drug graveyard: ARYx revives problem blockbuster drugs. Wolfson W Chem Biol; 2005 Nov; 12(11):1155-6. PubMed ID: 16298292 [No Abstract] [Full Text] [Related]
43. [The problem of pesticide and heavy metal residues in plant-derived drugs used in the pharmaceutical industry]. Lorusso S; Camoni I; Chiacchierini E Nuovi Ann Ig Microbiol; 1985; 36(3):169-80. PubMed ID: 3842759 [No Abstract] [Full Text] [Related]
44. [Metabolic effects in the resorption of drugs]. Kuhlmann J Med Klin; 1980 Nov; 75(23):802-12. PubMed ID: 7442595 [No Abstract] [Full Text] [Related]
45. Evidence used for approval of new drugs. Botstein P Isr J Med Sci; 1986; 22(3-4):197-200. PubMed ID: 3528042 [TBL] [Abstract][Full Text] [Related]
46. [Biologic availability of drugs in humans and animals]. Wichliński L Pol Tyg Lek; 1975 Dec; 30(50):2111-2. PubMed ID: 1197106 [No Abstract] [Full Text] [Related]
47. Bioavailability of drugs. Maitai CK East Afr Med J; 1982 Aug; 59(8):503-4. PubMed ID: 7173083 [No Abstract] [Full Text] [Related]
48. Drugs, industry, and academia. Fitzgerald GA Science; 2008 Jun; 320(5883):1563. PubMed ID: 18566251 [No Abstract] [Full Text] [Related]
49. Role of medical institutions in the development of new drugs. Sheth UK J Postgrad Med; 1976 Jan; 22(1):1-4. PubMed ID: 966182 [No Abstract] [Full Text] [Related]
50. The US drug safety system: role of the pharmaceutical industry. Gibson BR; Suh R; Tilson H Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741 [TBL] [Abstract][Full Text] [Related]
51. [Tendencies and outlook in drug research and development]. Nowotny OH Fortschr Med; 1978 May; 96(18):939-40, 951. PubMed ID: 648996 [No Abstract] [Full Text] [Related]
52. Evolva breeds small molecule drugs au naturel. Wolfson W Chem Biol; 2009 Jun; 16(6):577-8. PubMed ID: 19549594 [No Abstract] [Full Text] [Related]
53. Safety issues in scale-up of chemical processes. Stoessel F Curr Opin Drug Discov Devel; 2001 Nov; 4(6):834-9. PubMed ID: 11899622 [TBL] [Abstract][Full Text] [Related]
54. [Research on drug demand in the pharmaceutical organization]. Schubert M Pharm Prax; 1972; 11():250-3. PubMed ID: 4649577 [No Abstract] [Full Text] [Related]
55. Involving the pharmaceutical and biotech communities in medication development for substance abuse. Gorodetzky CW; Grudzinskas C Pharmacol Ther; 2005 Oct; 108(1):109-18. PubMed ID: 16038981 [TBL] [Abstract][Full Text] [Related]
56. [Kidney and drugs - urinary lithiasis. Pharmacokinetic glossary]. Balant L Rev Med Suisse Romande; 1980 Nov; 100(11):949-56. PubMed ID: 7466067 [No Abstract] [Full Text] [Related]
58. Pharmaceutical research at Hoechst. Schmidt-Thomé J Chem Ind; 1966 Mar; 10():427-9. PubMed ID: 5325078 [No Abstract] [Full Text] [Related]
59. Industrial perspective in ocular drug delivery. Ali Y; Lehmussaari K Adv Drug Deliv Rev; 2006 Nov; 58(11):1258-68. PubMed ID: 17079049 [TBL] [Abstract][Full Text] [Related]
60. A timely reassessment of early prediction in the bioavailability of orally administered drugs. Larsen T; Link A Angew Chem Int Ed Engl; 2005 Jul; 44(29):4432-4. PubMed ID: 15984039 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]